Jump to content

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs (Q27025525)

From Wikidata

scientific article published on January 21, 2012

Language	Label	Description	Also known as
default for all languages	No label defined
English	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs	scientific article published on January 21, 2012

Statements

scholarly article

1 reference

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs (English)

0 references

0 references

author name string

Dexin Kong

1

1 reference

Takao Yamori

2

1 reference

publication date

15 March 2012

1 reference

21 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22336246

25 December 2024

language of work or name

1 reference

work available at URL

https://doi.org/10.1016/j.bmc.2012.01.017

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22336246

25 December 2024

https://api.elsevier.com/content/article/PII:S096808961200034X?httpAccept=text/xml

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

https://api.elsevier.com/content/article/PII:S096808961200034X?httpAccept=text/plain

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Bioorganic & Medicinal Chemistry

1 reference

20

1 reference

6

1 reference

1947-51

1 reference

describes a project that uses

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1093/JNCI/83.11.757

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

2

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system

4

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics

5

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

6

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

New colorimetric cytotoxicity assay for anticancer-drug screening

7

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines

8

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Cancer Research

9

59

4042

author name string

Yamori

publication date

1999

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm

11

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.

12

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities

14

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Splicing factor SF3b as a target of the antitumor natural product pladienolide

15

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

In Vitro Cytotoxicity of Imidazolyl-1,3,5-triazine Derivatives

16

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

17

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers

18

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Signalling through the lipid products of phosphoinositide-3-OH kinase

19

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Advances in development of phosphatidylinositol 3-kinase inhibitors

20

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms

21

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest

22

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor

23

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase

24

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Discovery of Phosphatidylinositol 3-Kinase Inhibitory Compounds from the Screening Committee of Anticancer Drugs (SCADS) Library

25

1 reference

10.1016/J.BMC.2012.01.017

https://api.crossref.org/works/10.1016/J.BMC.2012.01.017

25 December 2024

Identifiers

10.1016/J.BMC.2012.01.017

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(1 entry)

zhwiki JFCR39

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27025525&oldid=2387340609"